---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000894"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:21:01.088948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Provectus outlines 2023 regulatory path for PV-10 in rare in-transit melanoma, updates pipeline

## Summary
- Plans regulatory pathway for PV-10 monotherapy to treat rare in-transit melanoma; cites 56% CR in 121 patients.
- Plans Phase 2/3 RCT of PV-10 + immune checkpoint blockade vs. monotherapy for Stage III melanoma; prior data shows 50% CR.
- 2022 achievements: 6 conference presentations, new patents, expanded research collaborations with Moffitt, Rockefeller, Univ. Calgary.
- Discovered PV-10 may act as immune adjuvant in vaccines; synthesized second HX molecule; added Dr. Aru Narendran to SAB.
- Received WHO INN name 'rose bengal sodium' for pharmaceutical-grade RBS API; option agreement with Univ. Miami for eye infections.

## SEC filing metadata
- accession: 0001493152-23-000894
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315223000894/0001493152-23-000894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315223000894/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000894
- JSON: https://secwatch.observer/filing/0001493152-23-000894.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.